Hot Off the Press – November 17 , 2020
Bossert et al. used a rat model of opioid agonist maintenance therapy to study the effect of the novel G-protein-biased mu opioid receptor (MOR) agonist TRV130 on relapse oxycodone seeking and taking during abstinence. They showed that TRV130 decreased oxycodone seeking and taking during abstinence in a partly sex-specific manner and prevented acute oxycodone-induced brain hypoxia. The authors proposed that G-protein-biased MOR agonists, currently in development as analgesics, should be considered as a relapse prevention maintenance treatment for opioid addiction. A translational clinical study at the IRP based on the results from the rat study of Bossert et al. is currently ongoing.
In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain Hypoxia Journal Article
Biological Psychiatry, 88 (12), pp. 935–944, 2020, ISBN: 0006-3223.